HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced that AOAC INTERNATIONAL has approved Bio-Rad’s iQ-Check Enterobacteriaceae Real-Time PCR Detection Kit, which is used to detect Enterobacteriaceae in dairy products. Enterobacteriaceae is a large family of gram-negative bacteria, which includes Escherichia coli, Salmonella, and others.
The iQ-Check Enterobacteriaceae Real-Time PCR Detection Kit method was validated against the ISO reference method using Bio-Rad’s PIF Supplement, which facilitates a shorter enrichment time for sample sizes up to 375 grams. Bio-Rad offers a fully harmonized enrichment protocol for real-time PCR and cultural methods to individually detect Enterobacteriaceae, Cronobacter, and Salmonella from a single sample, helping to decrease the costs, labor, and time associated with testing dairy products.
Although the ISO 21528-1:2017 approach to detection of Enterobacteriaceae is accurate, it is labor intensive and requires at least two days to screen for negative samples. The iQ-Check Enterobacteriaceae Real-Time PCR Detection Kit method matches the accuracy of the ISO method while reducing labor requirements and testing time.
To obtain approval, Bio-Rad participated in a validation study through AOAC INTERNATIONAL’s Performance Tested Methods (PTM) program. The study included 10 and 375 gram test portions of milk powder, powdered infant formula, and powdered infant formula with probiotics in addition to swabs from stainless steel taken from the processing plant environment. The samples were enriched for 18 to 22 hours with and without the PIF Supplement.
The approved method included a confirmation step with RAPID’Enterobacteriaceae Chromogenic Medium and showed no difference when compared to the reference method.
To learn more about iQ-Check Real-Time PCR Detection Kits for food safety testing, please visit bio-rad.com/iqcheck.
Learn more about the GelDoc Go Imaging System.
BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. IQ-CHECK is a trademark of Bio-Rad Europe GmbH in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,100 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.